Recent advances and emerging therapies in anaplastic thyroid carcinoma.

Maria E. Cabanillas; Mark Zafereo; Michelle D. Williams; Renata Ferrarotto; Ramona Dadu; Neil Gross; G. Brandon Gunn; Heath Skinner; Gilbert Cote; Horiana B. Grosu; Priyanka Iyer; Naifa L. Busaidy

doi:10.12688/f1000research.13124.1

Recent advances and emerging therapies in anaplastic thyroid carcinoma.

Maria E. Cabanillas, Mark Zafereo, Michelle D. Williams, Renata Ferrarotto, Ramona Dadu, Neil Gross, G. Brandon Gunn, Heath Skinner, Gilbert Cote, Horiana B. Grosu, Priyanka Iyer, Naifa L. Busaidy

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

Anaplastic thyroid cancer is a rare and aggressive thyroid cancer with an overall survival measured in months. Because of this poor prognosis and often advanced age at presentation, these patients have traditionally been treated palliatively and referred for hospice. However, recent progress using novel therapies has energized the field, and several promising clinical trials are now available for these patients. This review will highlight this progress and the potential treatments that could pave the way to improved outcomes and quality of life for patients with this disease.

Original language	English (US)
Article number	87
Journal	F1000Research
Volume	7
DOIs	https://doi.org/10.12688/f1000research.13124.1
State	Published - 2018

Keywords

Anaplastic thyroid cancer
BRAF
Chemotherapy
Dabrafenib
Dedifferentiated
NTRK
Sarcomatoid
Squamous
Targeted therapy
Trametinib
Undifferentiated
Vemurafenib

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology
General Immunology and Microbiology
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.12688/f1000research.13124.1

Cite this

@article{56751411e67c47da823ebef461f68cca,

title = "Recent advances and emerging therapies in anaplastic thyroid carcinoma.",

abstract = "Anaplastic thyroid cancer is a rare and aggressive thyroid cancer with an overall survival measured in months. Because of this poor prognosis and often advanced age at presentation, these patients have traditionally been treated palliatively and referred for hospice. However, recent progress using novel therapies has energized the field, and several promising clinical trials are now available for these patients. This review will highlight this progress and the potential treatments that could pave the way to improved outcomes and quality of life for patients with this disease.",

keywords = "Anaplastic thyroid cancer, BRAF, Chemotherapy, Dabrafenib, Dedifferentiated, NTRK, Sarcomatoid, Squamous, Targeted therapy, Trametinib, Undifferentiated, Vemurafenib",

author = "Cabanillas, {Maria E.} and Mark Zafereo and Williams, {Michelle D.} and Renata Ferrarotto and Ramona Dadu and Neil Gross and Gunn, {G. Brandon} and Heath Skinner and Gilbert Cote and Grosu, {Horiana B.} and Priyanka Iyer and Busaidy, {Naifa L.}",

note = "Publisher Copyright: {\textcopyright} 2018 Cabanillas ME et al.",

year = "2018",

doi = "10.12688/f1000research.13124.1",

language = "English (US)",

volume = "7",

journal = "F1000Research",

issn = "2046-1402",

publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - Recent advances and emerging therapies in anaplastic thyroid carcinoma.

AU - Cabanillas, Maria E.

AU - Zafereo, Mark

AU - Williams, Michelle D.

AU - Ferrarotto, Renata

AU - Dadu, Ramona

AU - Gross, Neil

AU - Gunn, G. Brandon

AU - Skinner, Heath

AU - Cote, Gilbert

AU - Grosu, Horiana B.

AU - Iyer, Priyanka

AU - Busaidy, Naifa L.

PY - 2018

Y1 - 2018

N2 - Anaplastic thyroid cancer is a rare and aggressive thyroid cancer with an overall survival measured in months. Because of this poor prognosis and often advanced age at presentation, these patients have traditionally been treated palliatively and referred for hospice. However, recent progress using novel therapies has energized the field, and several promising clinical trials are now available for these patients. This review will highlight this progress and the potential treatments that could pave the way to improved outcomes and quality of life for patients with this disease.

AB - Anaplastic thyroid cancer is a rare and aggressive thyroid cancer with an overall survival measured in months. Because of this poor prognosis and often advanced age at presentation, these patients have traditionally been treated palliatively and referred for hospice. However, recent progress using novel therapies has energized the field, and several promising clinical trials are now available for these patients. This review will highlight this progress and the potential treatments that could pave the way to improved outcomes and quality of life for patients with this disease.

KW - Anaplastic thyroid cancer

KW - BRAF

KW - Chemotherapy

KW - Dabrafenib

KW - Dedifferentiated

KW - NTRK

KW - Sarcomatoid

KW - Squamous

KW - Targeted therapy

KW - Trametinib

KW - Undifferentiated

KW - Vemurafenib

UR - http://www.scopus.com/inward/record.url?scp=85072930924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072930924&partnerID=8YFLogxK

U2 - 10.12688/f1000research.13124.1

DO - 10.12688/f1000research.13124.1

M3 - Review article

C2 - 31583077

AN - SCOPUS:85072930924

SN - 2046-1402

VL - 7

JO - F1000Research

JF - F1000Research

M1 - 87

ER -

Recent advances and emerging therapies in anaplastic thyroid carcinoma.

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this